Matchpoint Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $70M
Overview
Creating covalent small molecule drugs for immunological disorders.
Immunology
Technology Platform
Platform for discovering covalent small molecules that selectively target nucleophilic residues on disease-relevant proteins.
Funding History
1Total raised:$70M
Series A$70M
Opportunities
Potential for best-in-class profiles against validated immunology targets with improved dosing regimens.
Risk Factors
Risk of off-target covalent binding leading to toxicity, and potential immunogenicity of drug-protein adducts.
Competitive Landscape
Operates in the competitive immunology space, differentiating through a covalent chemistry approach to known targets.